Spencer Pharmaceutical Inc. Announces Submission of Patent Application Covering a New Technology of Dual Release Rate of Anti-In
02 Marzo 2011 - 9:02PM
Marketwired
Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) is pleased to
announce the submission of a patent application covering a
technology of dual release rate of anti-inflammatory drugs.
Results obtained by the group lead by Dr. Mateescu and Dr. Tien
Canh Le showed that our technology can produce monolithic tablets
rapidly liberating an effective dose of anti-inflammatory drug and
then sustaining the release for a longer duration. To the best of
our knowledge, these results are unique for monolithic tablets and,
we believe, can be extended to various drugs widely used in the
market. The patent also covers the use of our technology in several
anti-inflammatory drugs that can be formulated both as fast and
sustainable dual release. The excipients used are all GRAS
(generally recognized as safe).
"The Company would like to thank the tremendous work of Dr.
Mateescu and Dr. Tien Canh Le and their team who we believe have
made a breakthrough in the delivery of pain relief in this
multibillion dollar medical sector," stated Dr. Max Arella,
Chairman and CEO of Spencer Pharmaceutical Inc., Furthermore "It is
important to our shareholders to realize, that while we are
progressing through the due diligence phase of the offer previously
disclosed, we are committed to science first and that Spencer has
many other opportunities which we will be developing in the near to
medium term which, we believe, will add great value to our
Company," added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical
Research and Development Corporation, which is developing
innovative drug release and absorption systems for the treatment of
metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this
press release may be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "anticipate," "believe," "estimate," "expect,"
"intend" and similar expressions, as they relate to the company or
its management, identify forward-looking statements. These
statements are based on current expectations, estimates and
projections about the company's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual
outcomes and results may, and probably will, differ materially from
what is expressed or forecasted in such forward-looking statements
due to numerous factors, including those described above. In
addition, such statements could be affected by risks and
uncertainties related to the exploration for and development of
mineralized material, product demand, market and customer
acceptance, competition, pricing and development difficulties, as
well as general industry and market conditions and growth rates and
general economic conditions. Any forward-looking statements speak
only as of the date on which they are made, and the company does
not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of this
release. Information on the Company's website does not constitute a
part of this release. Although there is an offer currently coming
from a third party, the Company can provide no assurances that the
offer will be made, the timelines achieved, or the minimum offer
will be realized.
Contact: Ian Morrice Executive Vice President and
Director Spencer Pharmaceutical Inc. 1+(617) 973-5017
Grafico Azioni Spencer Pharmaceutical (CE) (USOTC:SPPH)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Spencer Pharmaceutical (CE) (USOTC:SPPH)
Storico
Da Set 2023 a Set 2024